ArticleCerebellum (London, England)2026
Auditory P300 Potentials as State Biomarkers for Mild-to-Moderate Depression in Spinocerebellar Ataxia Type 2.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a common comorbidity in spinocerebellar ataxia type 2 (SCA2). Despite P300 endogenous evoked potentials reliably indexing early cognitive deficits, their utility as depression biomarkers remains untested. This study aimed to characterize auditory P300 potentials as biomarkers of comorbid depression in SCA2 patients. Twenty SCA2 patients and age/sex-matched controls were stratified by Beck Depression Inventory-II (BDI-II) into depressed (≥ 14) and non-depressed (< 14) subgroups. Auditory P300 oddball paradigms were recorded, and P300 latency and amplitude analyzed in all participants. Two-way ANOVAs examined main effects and disease×depression interactions on P300 variables. SARA quantified ataxia severity. Two-way ANOVAs revealed significant main effects of disease group and depression status on P300 latency (rank-transformed data) and amplitude (parametric data), without significant interactions. Post-hoc Sidák tests confirmed prolonged latency and reduced amplitude in SCA2 patients vs. controls within both depression strata, and in depressed vs. non-depressed subgroups within each cohort. Spearman correlations demonstrated consistent P300-BDI-II relationships, but not associations between P300 parameters and SARA scores. ANCOVA confirmed independent depression effects on P300 parameters after covariate adjustment in SCA2. Auditory P300 latency and amplitude serve as state-dependent biomarkers for depression in SCA2, independent of motor progression. This supports P300 use as a secondary endpoint in clinical trials, enabling earlier diagnosis and precision medicine for affective symptoms.
Indexed as
Identifiers
42265332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.